PERROTTA, Fabio Massimo
 Distribuzione geografica
Continente #
EU - Europa 3.842
NA - Nord America 3.787
AS - Asia 1.135
SA - Sud America 358
AF - Africa 309
OC - Oceania 12
Continente sconosciuto - Info sul continente non disponibili 8
Totale 9.451
Nazione #
US - Stati Uniti d'America 3.697
RU - Federazione Russa 1.631
IE - Irlanda 772
SG - Singapore 497
BR - Brasile 289
CN - Cina 279
CI - Costa d'Avorio 270
IT - Italia 244
AT - Austria 194
FI - Finlandia 181
UA - Ucraina 166
DE - Germania 158
GB - Regno Unito 124
FR - Francia 93
VN - Vietnam 90
SE - Svezia 88
HK - Hong Kong 75
PL - Polonia 67
CA - Canada 60
IN - India 40
BE - Belgio 30
AR - Argentina 24
NL - Olanda 23
BD - Bangladesh 20
TR - Turchia 19
ES - Italia 18
MX - Messico 17
IQ - Iraq 16
JP - Giappone 16
LT - Lituania 16
CO - Colombia 15
ZA - Sudafrica 15
ID - Indonesia 14
AU - Australia 11
CL - Cile 8
EC - Ecuador 8
EU - Europa 8
IR - Iran 8
VE - Venezuela 8
EG - Egitto 7
KR - Corea 7
JO - Giordania 6
SA - Arabia Saudita 6
MA - Marocco 5
UZ - Uzbekistan 5
AE - Emirati Arabi Uniti 4
CH - Svizzera 4
IL - Israele 4
JM - Giamaica 4
LV - Lettonia 4
PT - Portogallo 4
TH - Thailandia 4
TN - Tunisia 4
AZ - Azerbaigian 3
BG - Bulgaria 3
CZ - Repubblica Ceca 3
DK - Danimarca 3
KE - Kenya 3
KZ - Kazakistan 3
LK - Sri Lanka 3
MY - Malesia 3
PA - Panama 3
BO - Bolivia 2
BY - Bielorussia 2
CY - Cipro 2
GR - Grecia 2
HU - Ungheria 2
KG - Kirghizistan 2
NI - Nicaragua 2
NO - Norvegia 2
NP - Nepal 2
PE - Perù 2
RO - Romania 2
RS - Serbia 2
TT - Trinidad e Tobago 2
AL - Albania 1
BB - Barbados 1
BW - Botswana 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
ET - Etiopia 1
IM - Isola di Man 1
LA - Repubblica Popolare Democratica del Laos 1
MK - Macedonia 1
MN - Mongolia 1
NZ - Nuova Zelanda 1
OM - Oman 1
PH - Filippine 1
PK - Pakistan 1
PY - Paraguay 1
SC - Seychelles 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
TJ - Tagikistan 1
TW - Taiwan 1
UY - Uruguay 1
Totale 9.451
Città #
Dallas 927
Dublin 772
Moscow 521
Chandler 439
Jacksonville 378
Abidjan 270
Singapore 270
Vienna 191
Helsinki 156
Ashburn 127
Ann Arbor 117
Wilmington 106
Beijing 105
San Mateo 78
The Dalles 75
Hong Kong 73
Los Angeles 67
Warsaw 67
Princeton 61
New York 57
Houston 56
Rome 54
Woodbridge 50
Columbus 47
Boardman 44
Dearborn 42
Ho Chi Minh City 36
São Paulo 31
Brussels 30
London 26
Toronto 22
Frankfurt am Main 20
Molise 20
Redwood City 20
Council Bluffs 19
Santa Clara 18
Brooklyn 17
Manchester 16
San Francisco 16
Tokyo 16
Jinan 14
Milan 14
Montreal 14
Ottawa 13
Amsterdam 12
Chicago 12
Denver 12
Johannesburg 12
Atlanta 11
Mountain View 11
Orem 11
Chennai 10
Falkenstein 10
Guangzhou 9
Hanoi 9
Nanjing 9
Rio de Janeiro 9
Seattle 9
Stockholm 9
Phoenix 8
Rochester 8
Augusta 7
Borås 7
Esslingen am Neckar 7
Leawood 7
Mexico City 7
Shanghai 7
Shenyang 7
Ankara 6
Ardabil 6
Baghdad 6
Fortaleza 6
Haikou 6
Istanbul 6
Ningbo 6
Rockville 6
Zhengzhou 6
Amman 5
Belo Horizonte 5
Boston 5
Brasília 5
Changsha 5
Dhaka 5
Falls Church 5
Jakarta 5
Newark 5
Poplar 5
Porto Alegre 5
Seoul 5
Taiyuan 5
Tashkent 5
Uberlândia 5
Curitiba 4
Da Nang 4
Fleet 4
Goiânia 4
Haiphong 4
Hefei 4
Juiz de Fora 4
Kingston 4
Totale 5.893
Nome #
Spondiloartriti assiali: dalla patogenesi della neoformazione ossea alla valutazione di possibili biomarcatori di attività di malattia e remissione clinica 267
An ultrasonographic study of enthesis in early psoriatic arthritis patients naive to traditional and biologic DMARDs treatment 216
An overview of low disease activity and remission in psoriatic arthritis. 178
An Assessment of Hand Erosive Osteoarthritis: Correlation of Radiographic Severity with Clinical, Functional and Laboratory Findings 178
Assessment of response to treatment, remission, and minimal disease activity in axial psoriatic arthritis treated with tumor necrosis factor inhibitors 176
Analysis of potential determinants for a treat-to-target strategy in psoriatic arthritis patients from a real-world setting 174
Assessment of subclinical atherosclerosis in ankylosing spondylitis: Correlations with disease activity indices 157
Beyond TNF Inhibitors: New Pathways and Emerging Treatments for Psoriatic Arthritis 155
Assessment of semaphorin 3A and its role in bone remodelling in a group of ankylosing spondylitis patients 155
Assessment of bone morphogenic protein 2 and interleukine-17A in patients with axial spondyloarthritis and their potential role in the new bone formation: a cross-sectional study 155
Chronic periaortitis with retroperitoneal fibrosis successfully treated with first line tocilizumab monotherapy: a case report 153
Assessment of the Patient Acceptable Symptom State (PASS) in psoriatic arthritis: Association with disease activity and quality of life indices 149
Beyond the joint: Subclinical atherosclerosis in rheumatoid arthritis 147
From clinical remission to residual disease activity in spondyloarthritis and its potential treatment implications 147
Remission in ankylosing spondylitis treated with anti-TNF-α drugs: a national multicentre study. 141
Cardiovascular Risk Prediction in Ankylosing Spondylitis: From Traditional Scores to Machine Learning Assessment 137
Case report of polymyalgia rheumatica in a male patient with three different neoplasms treated with pembrolizumab 134
Sustained Very Low Disease Activity and Remission in Psoriatic Arthritis Patients 132
Incidence of rheumatoid arthritis, psoriatic arthritis and polymyalgia rheumatica in an inland area of central Italy: results of the CAMPO-RHE study 130
Validity, responsiveness and feasibility of an Italian version of the Canadian Occupational Performance Measure for patients with ankylosing spondylitis 128
Assessment of widespread and extra-articular pain in psoriatic arthritis: a case-control study 127
Impact of Comorbidities on Disease Activity, Patient Global Assessment, and Function in Psoriatic Arthritis: A Cross-Sectional Study 122
Subcutaneous anti-TNF alfa induced sustained minimal disease activity and remission in psoriatic arthritis patients: a retrospective study 121
The role of IL-17 in the treatment of psoriatic arthritis 121
Mesenchimal stem cells: A possible role in the pathogenesis and treatment of spondyloarthritis 119
Residual disease activity in rheumatoid arthritis patients treated with subcutaneous biologic drugs that achieved remission or low disease activity: a longitudinal observational study 117
Clinical and ultrasonography assessment of peripheral enthesitis in ankylosing spondylitis 116
Patient's global assessment as an outcome measure for psoriatic arthritis in clinical practice: A surrogate for measuring low disease activity? 116
Secukinumab for ankylosing spondylitis and psoriatic arthritis 113
Comparison of composite indices tailored for psoriatic arthritis treated with csDMARD and bDMARD: A cross-sectional analysis of a longitudinal cohort 113
Unmet Needs in Axial Spondyloarthritis 112
Predictive factors for partial remission according to the Ankylosing Spondylitis Assessment Study working group in patients with ankylosing spondylitis treated with anti-TNFα drugs 110
Minimal Disease Activity and Remission in Psoriatic Arthritis Patients Treated with Anti-TNF-α Drugs 110
Validation of the Italian version of proposed GRAPPA flare questionnaire for patients with psoriatic arthritis 110
Role of comorbidities in spondyloarthritis including psoriatic arthritis 110
Predictors of loss of remission and disease flares in patients with axial spondyloarthritis receiving antitumor necrosis factor treatment: A retrospective study 109
Elderly psoriatic arthritis patients on TNF-α blockers: results of an Italian multicenter study on minimal disease activity and drug discontinuation rate 109
Dr. Lubrano, et al reply 109
Remission in nonradiographic axial spondyloarthritis treated with anti-tumor necrosis factor-α drugs: an Italian multicenter study. 108
Multimorbidity and comorbidity in psoriatic arthritis–a perspective 108
Cardiovascular comorbidities in psoriatic arthritis: epidemiology and risk factors in two different European populations 107
Defining low disease activity states in psoriatic arthritis using novel composite disease instruments 107
Clinical and imaging assessment of peripheral enthesitis in Ankylosing Spondylitis 105
Assessment of Patient-Physician Interactions in Psoriatic Arthritis: National Results of the ASSIST Study 104
Assessment of Carpal Tunnel Syndrome in Patients With Wrist Involvement During the Course of Inflammatory Arthritis. A Cross-Sectional Study 103
Dactylitis and Early Onset Psoriasis in Psoriatic Arthritis: Are they Markers of Disease Severity? A Clinical Study 98
Rapid effectiveness of certolizumab pegol in non-radiographic axial spondyloarthritis. 98
Constrictive Pericarditis With Massive Calcification in Systemic Sclerosis Treated With Pericardiectomy: A Case Report 97
Difficult-to-treat concept in Psoriatic Arthritis: analysis of two potential definitions in a large group of patients. A cross-sectional study 95
Psoriatic arthritis: is it time to treat-to-target or target to treat? 93
The sex influence on response to tumor necrosis factor-α inhibitors and remission in axial spondyloarthritis 93
Serum Sclerostin as a Possible Biomarker in Ankylosing Spondylitis: A Case-Control Study 92
Clinical Characteristics of Potential "Difficult-to-treat" Patients with Psoriatic Arthritis: A Retrospective Analysis of a Longitudinal Cohort 91
Impact of physical activity on disability risk in elderly patients hospitalized for mild acute diverticulitis and diverticular bleeding undergone conservative management 90
New approved drugs for psoriatic arthritis. 89
TNF-alpha inhibitors for the six treatment targets of psoriatic arthritis 89
Effectiveness of adalimumab for the treatment of psoriatic arthritis: An Italian real-life retrospective study 89
Occult axial involvement in patients with psoriatic arthritis mutilans: a case report 88
To move or not to move: The paradoxical effect of physical exercise in axial spondyloarthritis 87
The Conundrum of Psoriatic Arthritis: a Pathogenetic and Clinical Pattern at the Midpoint of Autoinflammation and Autoimmunity 86
Residual disease activity and associated factors in Psoriatic Arthritis 83
Improvement of Function and Its Determinants in a Group of Axial Spondyloarthritis Patients Treated with TNF Inhibitors: A Real-Life Study 82
Psoriatic arthritis, psoriatic disease, or psoriatic syndrome? 79
Ultrasonographic and Clinical Assessment of Peripheral Enthesitis in Patients with Psoriatic Arthritis, Psoriasis, and Fibromyalgia Syndrome: The ULISSE Study 78
Remission, low disease activity and improvement of pain and function in psoriatic arthritis patients treated with IL-12/23 and IL-17 inhibitors. A multicenter prospective study 78
New Insights in Physical Therapy and Rehabilitation in Axial Spondyloarthritis: A Review 77
Power Doppler ultrasonographic evaluation of enthesitis in psoriatic arthritis. A multi-center study 76
Rheumatology Care in the Face of COVID-19 72
Identification of the Minimal Disease Activity Domains Achieved Based on Different Treatments in Psoriatic Arthritis 68
The "Climb" Towards Minimal Disease Activity in Psoriatic Arthritis 67
Difficult to Treat and Refractory to Treatment in Psoriatic Arthritis 65
Clinical Characteristics of "Severe" Peripheral Psoriatic Arthritis: A Retrospective Analysis of a Longitudinal Cohort 64
Psoriatic Arthritis in Males and Females: Differences and Similarities 62
Ultrasound description of cortical-entheseal bone remodeling in peripheral entheses of patients with psoriasis and nonspecific musculoskeletal symptoms 62
Valutazione ecografica del tendine di Achille e dell'entesi rotulea nei giocatori di calcio e basket: potrebbe essere utile per prevedere lo sviluppo di lesioni muscolari e tendinee? 61
SARS-CoV-2 IgM False-Positivity in a Psoriatic Arthritis Patient Seropositive for Rheumatoid Factor and ACPA: An Interference of Immune Response? 59
New Insights in Physical Therapy and Rehabilitation in Psoriatic Arthritis: A Review 55
MRI Assessment of Extra-axial Findings at Pelvic Sites in a Group of Axial-SpA Patients 55
Long-Term Survival of Methotrexate as First-Line Therapy in Rheumatoid Arthritis, Psoriatic Arthritis and Undifferentiated Arthritis 54
Therapeutic Targets for Ankylosing Spondylitis - Recent Insights and Future Prospects 52
Extra-Articular Manifestations and Comorbidities in Psoriatic Disease: A Journey Into the Immunologic Crosstalk 52
Valutazione dei fattori predittivi per il raggiungimento della remissione parziale (RP) secondo i criteri ASAS nei pazienti con Spondilite Anchilosante (SA) trattati con farmaci antagonisti del TNF 51
Sequencing of Biologic and Target Synthetic Disease-Modifying Anti-Rheumatic Drugs in Psoriatic Arthritis: Are we Ready to Redefine the Treatment Strategy? A Perspective 50
Inflammatory bowel disease manifestations in spondyloarthritis: considerations for the clinician 50
Ultrasonographic Evaluation of Entheseal Fibrocartilage in Patients with Psoriatic Arthritis, Athletes and Healthy Controls: A Comparison Study 49
Patient reported outcomes in early vs late diagnosis of psoriatic arthritis|Resultados informados por los pacientes en el diagnóstico precoz respecto a los pacientes con diagnóstico tardío en la artritis psoriásica 48
Livelli aumentati di IL19 nel liquido sinoviale di pazienti con artrite psoriasica 46
Use of Ultrasonography to Discriminate Psoriatic Arthritis from Fibromyalgia: A Post-Hoc Analysis of the ULISSE Study 45
The holistic management of peripheral spondyloarthritis: focus on articular involvement in patients with inflammatory bowel disease 44
Psychological Health in the Management of Patients with Psoriatic Arthritis: An Intricate Relationship 43
Evaluation of the “Multivariable Psoriatic Arthritis Risk Estimation Tool” in a Cohort of Patients with Psoriasis: Preliminary Results of a Prospective Observational Study 42
Visceral muscle dysmotility syndrome in systemic lupus erythematosus: which is the role of 18 fluorodeoxyglucose-positron emission tomography-computed tomography? A clinical case and literature review 42
Triple jump for the optimal management of psoriatic arthritis: Diet, sleep and exercise - A review 40
Sex-related differences in psoriatic arthritis 37
Male Fertility in Spondyloarthritis: from Clinical Issues to Cytokines Milieu. A Narrative Review 36
The assessment of the drug retention rate of secukinumab in patients with psoriatic arthritis in a real-life multicentre cohort 36
Elevated levels of IL-19 in the joints of patients with psoriatic arthritis 36
Two sides of management recommendations for psoriatic arthritis 35
VALUTAZIONE DELLA REMISSIONE CLINICA SECONDO I CRITERI ASAS NEI PAZIENTI CON SPONDILOARTRITE ASSIALE TRATTATI CON FARMACI BIOLOGICI ANTAGONISTI DEL TNF ALPHA: STUDIO RETROSPETTIVO MULTICENTRICO 33
Sensitivity and Specificity of Composite Indices of Remission in Male and Female Patients With Psoriatic Arthritis: A Multicenter Cross-Sectional Study of Longitudinal Cohorts 32
Totale 9.586
Categoria #
all - tutte 46.776
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 46.776


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021315 0 0 0 0 0 28 76 12 76 15 99 9
2021/2022359 15 76 16 17 17 7 10 38 49 71 14 29
2022/20231.805 218 74 34 151 68 126 15 86 895 67 39 32
2023/2024473 132 68 34 19 23 51 2 33 17 23 19 52
2024/20251.668 319 69 193 21 285 36 21 96 163 55 174 236
2025/20263.596 205 482 705 377 1.418 409 0 0 0 0 0 0
Totale 9.613